MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer
In summary, our findings underscore the pivotal role of MED12 in remodelling immnue TME through the epigenetic silencing of retrotransposons, offering a potential therapeutic target for enhancing tumour immunogenicity and overcoming immunotherapy resistance in PDAC.
Authors
- Massimiliano Mazzone (ORCID: https://orcid.org/0000-0001-8824-4015)
- Christian Pilarsky (ORCID: https://orcid.org/0000-0002-7968-3283)
- Yongwei Sun (ORCID: https://orcid.org/0000-0002-5937-634X)
- Zhengyan Zhang (ORCID: https://orcid.org/0000-0002-4906-4481)
- Jing Xue (ORCID: https://orcid.org/0000-0002-6497-1792)
- Chaochen Wang (ORCID: https://orcid.org/0000-0003-2346-2884)
- Yujie Tang (ORCID: https://orcid.org/0000-0001-7647-5780)
- Yu Wang (ORCID: https://orcid.org/0000-0003-2271-7371)
- Ruijun Tian (ORCID: https://orcid.org/0000-0001-9521-5124)
- Wenjuan Yang (ORCID: https://orcid.org/0000-0001-7270-8356)
- Yingying Tang
- Junyi Xu
- Shijie Tang (ORCID: https://orcid.org/0009-0008-3917-643X)
- Lei-Wei Wang
- Yuyun Wu
- Teng Wang
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Southern University of Science and Technology (CN)
- Universitätsklinikum Erlangen (DE)
- VIB-KU Leuven Center for Cancer Biology (BE)
- Shanghai Cancer Institute (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Zhejiang University-University of Edinburgh Institute (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Gut
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1136/gutjnl-2024-332350
- Citations
- 11
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.11